As of 2025, the Hospital Corporation of America, based in Nashville, Tennessee, was the largest health system in the United States, with a total of ****** hospital beds. HCA Healthcare is also the largest U.S. health system when ranked by the number of hospitals and net patient revenue. Altogether, the largest ** healthcare systems or integrated delivery networks (IDNs) cover ******* hospital beds. Most of these health systems are non-profit organizations.

As of 2023, Kaiser Permanente, based in Oakland, California, was the largest health system in the United States when ranked by the number of physicians affiliated with the system. It had nearly 26 thousand physicians affiliated with the organization. Meanwhile, the Hospital Corporation of America, based in Nashville, Tennessee, was in second place when ranked by the number of physicians, but was the largest health system in the United States when ranked by the number of hospitals. HCA Healthcare is also the largest U.S. health system when ranked by the number of beds and, as expected, by net patient revenue.

In 2024, UnitedHealthcare Group was the largest health insurance company in the United States by revenue with over *** billion U.S. dollars, followed by ******** *************** and *****************. This statistic shows the ten largest healthcare companies in the U.S. in 2024, by revenue.

Hospitals play a critical role in healthcare, offering specialized treatments and emergency services essential for public health, regardless of economic fluctuations or individuals' financial situations. Rising incomes and broader access to insurance have fueled demand for care in recent years, supporting hospitals' post-pandemic recovery initiated by federal policies and funding. The recovery for many hospitals was also promoted by mergers that lessened financial strains, especially in rural hospitals. This trend toward consolidation has resulted in fewer enterprises relative to establishments, enhancing hospitals' bargaining power regarding input costs and insurance reimbursements. With this improved position, hospitals are expected to see revenue climb at a CAGR of 2.0%, reaching $1.5 trillion by 2025, with a 3.2% increase in 2025 alone. Competition, economic conditions and regulatory changes will impact hospitals based on size and location. Smaller hospitals, particularly rural ones, may encounter more significant obstacles as the industry transitions from fee-based to value-based care. Independent hospitals face wage inflation, staffing shortages and drug supply costs. Although state and federal policies aim to support small rural hospitals in addressing hospital deserts, uncertainties linger over federal Medicare funding and Medicaid reimbursements, which account for nearly half of hospital care spending. Even so, increasing per capita disposable income and increasing the number of individuals with private insurance will boost revenues from private insurers and out-of-pocket payments for all hospitals, big and small. Hospitals will continue incorporating technological advancements in AI, telemedicine and wearables to enhance their services and reduce cost. These technologies aid hospital systems in strategically expanding outpatient services, mitigating the increasing competitive pressures from Ambulatory Surgery Centers (ASCs) and capitalizing on the increased needs of an aging adult population and shifts in healthcare delivery preferences. As the consolidation trend advances and technology adoption further leverages economies of scale, industry revenue is expected to strengthen at a CAGR of 2.4%, reaching $1.7 trillion by 2030, with steady profit over the period.

Specialty hospitals have seen positive growth despite Medicare and Medicaid funding fluctuations, swings in the number of insured individuals and changes in per capita disposable income. Supportive non-operating investment income and diverse payor sources have supported continued revenue growth. At the same time, substantial government funding during the pandemic and waivers permitting the implementation of telehealth allowed hospitals to weather short-term demand and cost shocks. Despite the variability in funding and demand shock, revenue grew at a CAGR of 2.1% to $64.7 billion in 2024, with revenue increasing by 1.2% in 2024 alone. Mergers and consolidation continue to be prevalent trends among specialty hospitals. Belonging to a larger hospital chain allows specialty hospitals to benefit from economies of scale and increased access to innovation. Consolidation empowers specialty hospitals in health insurance contract negotiations, resulting in favorable prices. Also, larger establishments can negotiate more favorable terms with suppliers of critical inputs, leading to decreased costs and increased profit. Technological innovation has been pivotal in enhancing care quality and reducing operational costs, and smaller independent specialty hospitals may face challenges in bringing this quality to the market. Considerable investment required to procure advanced technology at large general hospitals puts smaller, unaffiliated specialty hospitals at a disadvantage. The outlook for specialty hospitals remains positive. With the growth in Medicaid and Medicare funding continuing at previous levels and a healthy economy supporting increased private insurance coverage, revenue and profit will climb. While state-level Certificate of Need (CON) laws may influence geographic concentration and boost competition, the hospital chain organizational trend will strengthen negotiating capabilities with insurance companies and suppliers. Specialty hospitals are emphasizing outpatient services, including advanced same-day surgeries. This shift is driven by patient preference, cost-efficiency and innovations such as minimally invasive procedures. Advancements in telehealth and remote monitoring will let hospitals manage post-surgery care effectively, reducing inpatient admissions. Lastly, demographic and preference shifts (a growing adult population with a higher prevalence of chronic diseases and a younger demographic benefiting from state-of-the-art technology) will drive customers to seek healthcare services at specialty hospitals. Revenue is forecast to rally at a CAGR of 2.9% through 2029 to total $74.6 billion and profit increasing to 14.7%.

The services offered by psychiatric hospitals are extensive, covering specialized facilities like detox centers, mental health hospitals providing comprehensive care and addiction hospitals focusing on substance use disorders. Some facilities are equipped to offer integrated services for individuals with multiple diagnoses. This growth indicates both rising demand and increased public awareness of mental health and substance use issues. However, geographic disparities, especially in the West, where uneven population distribution creates service provision challenges. The financial stability of these hospitals heavily depends on payor distribution. Medicare and Medicaid contribute about a quarter of the revenue, while third-party insurers provide nearly two-thirds. Economic conditions impact these payors differently, influencing hospital revenue, operational costs and profitability. During economic downturns, cuts in government funding may reduce revenue and changes in private insurance markets can influence patient volumes. Despite initial challenges from the health crisis, government and public insurance coverage have stimulated growth. Industry revenue will climb at a CAGR of 1.1% through 2025, reaching $35.3 billion, with a 3.0% increase in 2025 alone. Innovation and consolidation are transforming hospital services and organizational structures. Artificial intelligence, teletherapy and virtual reality enhance service offerings and patient outcomes. AI aids diagnosis and personalizes treatment, while teletherapy improves access, especially in underserved areas. Virtual reality introduces novel treatment options, appealing to patients seeking advanced therapies. Also, mergers and acquisitions and an increase in the number of hospital affiliations with chains promote financial stability and competitive strength. Larger organizations leverage resources to invest in infrastructure and negotiate favorable terms with insurers, helping them stay competitive despite rising staffing costs. Future federal policy might influence consumer demand and access to psychiatric services. The reorganization under the Administration for a Healthy America (AHA) may involve budget, staff and reimbursement cuts, potentially reducing service demand and access to grants and support. State-specific reductions in Medicaid funding could destabilize hospitals reliant on these reimbursements. Even so, economic factors are expected to drive overall growth. Increases in per capita disposable income, an increase in the number of privately insured individuals and growing health expenditures will bolster funding for hospital services. Industry revenue is projected to grow at a CAGR of 2.4%, reaching $39.7 billion by 2030, with profit revenue share remaining constant.

The industry has encountered challenging conditions, with revenue falling at a CAGR of 1.2% to $28.5 billion over the past five years, despite a bump of 4.9% in 2023 alone. Hospitals have met a high degree of fiscal uncertainty via to the whittling down of the Patient Protection and Affordable Care Act (PPACA) from the prior administration, while a renewed focus on it by the Biden administration has already boosted the number of health-insured consumers, bolstering demand for hospital construction. From legislative hurdles to the global pandemic outbreak causing construction stoppages amid a surge in demand for hospital capacity, the industry has endured significant volatility.The industry includes private and public hospital construction, though private hospital construction makes up nearly 80.0% of the total. Growth in the value of both private and public hospital construction has been insufficient to keep up with inflation. This inconsistency in private and public markets helps to explain the halt in industry revenue growth, while at a broader level, hospitals have opted to shift acute care services to off-campus locations to reduce costs and reach a larger patient pool. The move has helped hospitals mitigate lower admission and inpatient days, but these facilities are smaller and generate less revenue for enterprises. As demand for hospital space in 2020 skyrocketed amid the pandemic, the industry couldn't respond rapidly due to local and state work stoppages.Going forward, revenue growth for the industry will resume as total health expenditure remains strong and the value of private nonresidential construction fully recovers and accelerates ahead of declines exhibited during the pandemic. As the population ages, a rising senior demographic will embolden demand for hospital services. In the post-pandemic world, government support for hospital capacity will also rise, benefiting industry performance. Overall, industry revenue is slated to grow at a CAGR of 3.0% to an estimated $33.0 billion in 2028 as profit recovers to 3.3%.

Health and medical insurance companies experienced significant fluctuations in performance in recent years. The onset of COVID-19 led to a substantial increase in healthcare spending in 2020 and 2021, as demand for medical services surged. Consequently, investment in health insurance witnessed a dramatic rise, contributing to robust revenue growth during these years. However, with inflation peaking in 2022, consumer purchasing power diminished, causing households to reduce their spending on health insurance. This factor, coupled with a slowdown in health expenditure growth as the immediate pandemic effects waned, resulted in meager revenue growth for insurers in 2022, a notable deceleration compared to prior years. The industry performed better in 2023 as low inflation enabled consumers to more easily afford health insurance, with revenue then rising significantly in 2024 due to soaring investment income. More broadly, providers have been influenced by slowing healthcare inflation, despite a historically rapid rise in prior decades. For example, from 1970 to 2010, health expenditures skyrocketed, buoyed by substantial innovations. However, recent years have seen this growth plateau. This is attributed to a shift toward less costly innovation, focusing more on pharmaceutical advancements rather than costly healthcare system overhauls. Consequently, providers have faced slower revenue growth. Consolidation has risen as the industry’s largest players have used economies of scale, acquisitions and advertising to take over more of the market. Regardless, internal competition has soared as more providers have entered the industry to capture new revenue streams due to rising short-term health spending and the aging of the US population, constraining profit. Overall, revenue for health and medical insurance companies has swelled at a CAGR of 3.8% over the past five years, reaching $1.5 trillion in 2025. This includes a 2.5% rise in revenue in that year. The industry's landscape is set for further evolution over the next five years. Anticipated steady economic growth, with GDP projected to rise and unemployment to remain low, is likely to bolster health insurance revenue streams, primarily through heightened spending on employer-sponsored and private health plans. However, the potential for economic disruptions, such as the implementation of tariffs, could affect providers’ stability. As the population ages and healthcare demand grows, insurers will seek to tailor their policies to address the needs of an older demographic, necessitating comprehensive services. Overall, revenue for health and medical insurance providers is forecast to expand at a CAGR of 2.7% over the next five years, reaching $1.8 trillion in 2030.

Institutional pharmacies have consolidated and generated solid revenue growth over the past five years. The aging population and rising obesity rates are leading to higher incidences of age-related health conditions that are filling hospitals and depleting healthcare providers' pharmaceutical supplies faster. Increased federal support has offset declining private insurance coverage brought by inflation and a shaky job market. Increased funding for Medicare and Medicaid has strengthened the financial health of institutional pharmacies' main clients as patients seek both essential and elective treatments. Major companies' dominance has allowed them to acquire competitors and boost profit. Revenue has been swelling at a CAGR of 1.2% to an estimated $24.8 billion over the five years through 2024, including an expected 0.9% uptick in 2024 alone. The contrast between brand-name and generic drugs significantly impacts institutional pharmacies. Brand-name medications are extremely expensive but especially lucrative for institutional pharmacies as healthcare providers have no choice but to purchase brand-name drugs to treat patients who may not respond well to generic alternatives. Brand-name pharmaceuticals' patents expire after some years, leading to the approval and release of more affordable generic substitutes. Still, the approval of new brand-name medications is expected to counterbalance revenue dips from patent expirations. Institutional pharmacies contend with little supplier power, so they can pass rising input costs downstream and protect profit. Demographics will continue to support institutional pharmacies' clients through the next five years. Adults aged 50 and older will form a larger part of the population, boosting demand for healthcare services and long-term care facilities. Institutional pharmacies will remain essential to keeping providers equipped to treat their patients' needs. Strong federal support with increased Medicare and Medicaid funding will create opportunities for new market entrants, though concentration is expected to continue rising. Major institutional pharmacies will leverage economies of scale to adapt to regulatory challenges, ensuring a resilient future with expanded offerings and specialized services. Revenue is set to climb at a CAGR of 2.2% to $27.7 billion through the end of 2029.

Physical therapists will be in greater demand because of demographic shifts, evolving healthcare trends and cost-effective treatments. An aging population has boosted the need for physical therapy (PT) to manage age-related conditions. PT has become a cost-effective solution amid rising healthcare expenditures and the transition to value-based care models. However, despite these growth drivers, the industry faced disruptions from the pandemic, which reduced patient volumes and created backlogs in care. Although patient numbers have recovered, the long-term growth trend has been subdued by ongoing pressures such as workforce shortages and climbing costs. From 2020 to 2025, the physical therapy industry grew at a CAGR of 3.8%, or 2.8%, when adjusted for the significant drop in 2020. By 2025, the industry's revenue is expected to reach $53.1 billion, although rising wages have reduced profit. Consolidation is a stability-seeking strategy after a period of volatility, slower revenue growth and lower profit. The discretionary nature of some PT services makes the field vulnerable to fluctuations. Since revenue is tied to insurance coverage and economic shifts, it often leads patients to defer or cancel appointments in favor of more urgent medical needs. Changes in healthcare policies, reimbursement rates and new licensing standards add complexity and costs. These factors encourage smaller clinics to consolidate by partnering with larger health systems or private equity-backed organizations to benefit from economies of scale and access to capital. Meanwhile, the increasing use of teletherapy and wearable tech is furthering delivery to distant markets beyond traditional geographic limits, reducing economic volatility. Looking ahead, technological innovations and consumer-driven healthcare will expand the quality and variety of services and promote competition. An aging population will continue to drive demand, particularly in preventive care and in-home therapy, alleviating healthcare system burdens. As consumerism flourishes, therapists have the opportunity to carve out specialty niches, leveraging niche services to cater to varied patient expectations and preferences. Non-traditional competitors entering the PT space blur the lines between health and wellness, fostering a more competitive landscape. While changes in regulation and reimbursements may dampen revenue, establishments can reduce the impact by expanding cash-based services and merging with other suppliers to reduce costs and afford state-of-the-art equipment. By 2030, industry revenue is expected to climb at a CAGR of 2.4%, reaching $59.7 billion 2030.

Over the five years to 2023, Medical Equipment Rental industry companies have exhibited growth due to the rapid advent of high-cost equipment. As many healthcare providers have struggled with cuts to Medicare and Medicaid reimbursements, they have implemented cost-saving strategies. Some providers have chosen to rent rather than purchase medical equipment to access up-to-date technologies at a lower cost. In addition, rising total health expenditure from the expanding medical needs of an aging US population has increased demand for industry services from both hospitals and home healthcare providers. In all, over the five years to 2023, industry revenue is projected to increase at a CAGR of 1.7% to $4.9 billion, including growth of 0.3% in 2023. Industry profit, measured as earnings before interest and taxes, is expected to account for 16.3% of revenue in 2023.The onset of the COVID-19 pandemic created significant disruptions across the healthcare sector (IBISWorld report 62). As the number of patients admitted to hospitals grew exponentially, hospitals simultaneously experienced a limited supply of critical equipment while shifting resources toward a pandemic response, increasing demand for medical equipment rentals. While widespread vaccine availability reduced patient admissions in 2021, supply chain disruptions continue to restrict access to essential medical equipment, elevating industry demand above pre-pandemic levels. Recovery in total health expenditure, fueled largely by pent-up demand for health services, including elective surgeries, is expected to drive revenue growth between 2022 and 2023 as well.Over the five years to 2028, industry revenue is forecast to continue to grow. During the next five-year period, the industry will be characterized by rising demand from healthcare institutions and homecare providers to meet the medical needs of an aging population. As the ongoing shift from volume-based models to value-based care occurs, demand for medical equipment rentals is expected to rise as healthcare providers seek the latest in evolving medical technologies for patient care to improve outcomes. Overall, industry revenue is expected to rise at a CAGR of 1.7% to $5.4 billion over the five years to 2028.

Major companies have continued to dominate medical device manufacturing, making strategic acquisitions and heavily investing in research and development (R&D) to boost market share. Industry giants like Johnson & Johnson and Boston Scientific have actively pursued acquisitions to expand their portfolios and strengthen their market positions. Johnson & Johnson's 2022 acquisition of Abiomed fortified its place in treating cardiovascular diseases, and Boston Scientific's 2023 acquisition of Axionics expanded its urology product offerings. At the same time, high demand for healthcare from the aging population has made room for an influx of start-ups. Revenue has been climbing at a CAGR of 1.2% to an estimated $56.4 billion over the five years through 2025, including an expected lift of 3.1% in 2024 alone. Innovation has remained a pivotal element in securing growth for medical device manufacturers. Advances in technology and research have led to the development of sophisticated products that can treat rare chronic conditions and ailments. New smart implantable devices, like Biotronik's Dynagen A3 cardiac defibrillator, enhance physicians' ability to treat patients. Government support has been a solid boon for manufacturers, with initiatives like revamped R&D tax credits fuelling innovation. Medical device manufacturers are increasingly focusing on personalizing products and integrating AI, as seen with Medtronic's Genius GI endoscopy tool, allowing them to cater to specific patient needs and improve healthcare outcomes. Since healthcare professionals are under pressure to use the best tools available, the release of new innovative products has directly spurred sales and pushed revenue upward. Buyers' reliance on effective medical devices gives manufacturers significant control over prices, allowing them to maintain solid profit despite swelling R&D budgets. Demographic changes and technological advancements will continue enabling medical device manufacturers to drive revenue growth. As the median age of the U.S. population climbs, demand for orthopedic and neurological devices will surge. Companies will continue investing heavily in R&D to outpace competition in domestic and international markets. Upcoming regulatory changes and potential tariffs under the second Trump administration could present opportunities and challenges, easing regulations but deterring international trade. Despite these hurdles, revenue is set to outpace the previous period's growth, surging at a CAGR of 2.6% to an estimated $64.3 billion through the end of 2030.

Intravenous (IV) solution manufacturers have a critical role in healthcare delivery, supplying essential fluids like saline and dextrose used in virtually every care setting, from hospitals and surgical centers to outpatient infusion clinics. Historically, demand has remained stable and predictable, linked closely to procedure volumes and inpatient utilization. However, over the past five years, demand has accelerated because of a shift toward outpatient care, the rise of home infusions and growth in chronic disease management. The expansion of ambulatory surgery centers (ASCs) and non-hospital care sites has also created new, decentralized demand for IV fluids, increasing the number of delivery points. Despite being a commoditized product, IV solutions are volume-driven and critical to day-to-day patient care, which places pressure on manufacturers to deliver a consistent supply at a low price. The rising purchasing power of group purchasing organizations (GPOs) has intensified price competition among manufacturers, pushing prices lower and making it challenging for suppliers to invest in new capacity or product innovation. In all, revenue has risen at a CAGR of 0.2% to an estimated $3.4 billion over the past five years, including expected growth of 3.2% in 2025. In 2024, the industry’s vulnerability was exposed when Hurricane Helene severely disrupted Baxter’s North Cove facility in North Carolina, the single largest US producer, with this single facility accounting for roughly 60% of the national IV fluid supply. The flooding led to an immediate nationwide shortage, forcing hospitals to ration fluids and scramble for backup suppliers. The event highlighted the pitfalls of a highly concentrated industry where a handful of facilities produce nearly all the domestic supply. While competitors like B. Braun ramped up output and FEMA authorized emergency imports, the shortage underscored how disruptions have system-wide effects. The disruption at Baxter’s North Cove facility caused its market share to drop as hospitals and GPOs shifted orders to competitors like B. Braun and imports. This event pushed health systems and buyers to diversify their supplier base, weakening reliance on any single manufacturer and potentially prompting a long-term shift in market dynamics. IV solution manufacturing is expected to grow moderately, driven by outpatient expansion, aging demographics and increased chronic care treatment. However, growth will be uneven across settings: while hospitals remain the largest customers, infusion clinics and home care are driving new demand that requires more nimble packaging and distribution models. Manufacturers will be under pressure to modernize facilities, diversify geographic production and improve risk management capabilities. Long-term, demand will continue rising, but aggressive GPO pricing, high regulatory costs and the commoditized nature of the product will constrain profit. New competitors, including a Saudi-based IV production facility (announced in May 2025 in Trump’s Saudi-US economic partnership), could introduce headwinds too. Investments in automation and efficiency will be essential for manufacturers to remain competitive, control costs and maintain reliability. Revenue will expand moving forward, increasing at a CAGR of 2.3% to an estimated $3.9 billion over the next five years.

The industry has exhibited measured growth over the past five years, supported by steady activity among its largest downstream markets. Healthcare sectors, including hospitals and outpatient care facilities, have maintained consistent purchases because of strict sanitation requirements. School systems and educational institutions have also sustained demand for disinfectant products to meet health and safety guidelines. Food service businesses, ranging from restaurants to large-scale cafeterias, have routinely sourced disinfectants to satisfy hygiene standards imposed by local regulations. Economic activity in these industries has provided a reliable flow of orders, helping to stabilize demand for manufacturers. Contract cleaning services used in office buildings, government facilities and hospitality venues have served as additional consumption channels. Fluctuations in commercial real estate occupancy and restaurant foot traffic have occasionally influenced order volumes, but industry-wide shifts have not been dramatic over the past five years. Regulatory updates on chemical use and sanitation standards have indirectly bolstered demand in certain downstream industries, increasing their reliance on specialized disinfectant products. Over the past five years, sustained order flow from healthcare and educational institutions has fueled steady industry growth. Downstream buyers have prioritized compliance and reliability over cyclical cost variations, which has minimized the volatility experienced by producers. Healthcare users, dealing with mandatory sanitation rules, have remained less sensitive to price and more focused on consistency and stock availability. Commercial and institutional buyers in the cleaning and hospitality markets have mirrored this trend, although economic slowdowns have occasionally moderated bulk purchasing. Industry profit, meanwhile, has been constrained by the pace of wage growth among manufacturing workers, which increased operational expenses as companies competed for skilled labor. Input costs such as packaging materials, including plastic containers and closures, have played a key role in pressuring profit because of global supply chain tightness. Price increases for chemical feedstocks tied to oil and commodity costs have also contributed to cost pressures. Regulatory compliance requirements added another layer of expenses, particularly for products seeking approval under the US Environmental Protection Agency guidelines. Demand stability among downstream users has made up for some of these impacts, but overall profit has been diluted by elevated labor and material costs. Disinfectant Manufacturing industry revenue has been inching upward at a CAGR of 0.2% over the past five years and is expected to total $4.6 billion in 2025, when revenue will jump by an estimated 3.5%. The next five years will see revenue expansion as major downstream markets remain robust. Investment in new hospital construction and the renovation of existing medical buildings will increase requirements for advanced disinfectant solutions. Upgrades to ventilation and cleaning infrastructure in schools will drive enhanced purchasing of specialized disinfectants. US-based food processing and packaging plants, facing growing export and domestic demand, will rely on expanded sanitation protocols, supporting industry growth. Economic activity in building management and property maintenance will remain a steady source of bulk orders, especially as commercial properties update their health standards. Packaging manufacturers who supply disinfectant producers will continue to see orders rise as companies introduce new delivery formats such as wipes and sprays. Growth in the US restaurant and institutional food service industry will encourage greater consumption of surface and equipment disinfectants. Upward momentum in the healthcare sector, fueled by demographic changes and increased patient volumes, will require ongoing investment in cleaning products. Disinfectant Manufacturing industry revenue is expected to expand at a CAGR of 2.9% to $5.4 billion over the five years to 2030.

The Speech-Language Pathologists industry has experienced steady conditions and stable revenue growth. The industry, which comprises health practitioners that primarily evaluate, diagnose and treat speech, language, cognitive-communication and swallowing disorders, typically services clients in school facilities, healthcare facilities and hospitals. Furthermore, increased access to health insurance due to healthcare reform has enabled individuals to afford industry services, as many speech-language pathology services are covered by health insurance. Industry-wide revenue has been growing at a CAGR of 0.2% over the past five years and is expected to total $5.0 billion in 2024 when revenue will rise by an estimated 1.0%. The passage of the Patient Protection and Affordable Care Act (PPACA) in 2010 has been a boon to the industry. Under the healthcare reform law, subsidized state and federal healthcare exchanges have expanded private health insurance enrollment despite the individual mandate's repeal. As a result, more individuals have obtained personal health insurance coverage over the past decade, enabling them to access industry services. Moreover, healthcare reform has increased the number of individuals with government health insurance by expanding access to Medicaid in states that decided to participate in the expanded Medicaid program. Growth of the industry's major markets, student and elderly populations, is expected to remain strong. In particular, the aging population will increase demand for industry services as people typically require more medical care as they age. Although access to industry services will increase due to expanding health insurance rolls, the industry is expected to contend with pressure from Medicare reimbursement rates, limiting profit growth over the coming years. Nonetheless, industry revenue is forecast to grow at a CAGR of 1.4% over the five years through 2029 to total $5.4 billion.

Ambulance service providers have faced revenue volatility resulting from pandemic-driven emergency services demand, increases in operating costs and upward pressure on wages. And following the national health emergency, supportive government funding declined and growth in private insurance slowed, limiting revenue growth. The pandemic highlighted the convenience and cost advantages of substitute nonemergency services (Uber Health, Lyft Healthcare, telehealth and walk-in clinics), adding competitive pressures that stifled revenue growth and providers' profit. Fortunately, despite the challenges, industry-wide revenue is expected to climb at a CAGR of 2.1% to a total of $22.0 billion in 2025, when revenue will rally by an estimated 3.3% in 2025 alone. The industry is experiencing a trend of increasing public-private partnerships. As municipalities aim to cut costs because of state budgetary issues (especially in rural areas), they're increasingly outsourcing ambulance services and realizing cost savings through economies of scale. These cost savings can spur increased competition, benefiting some providers while forcing less efficient providers to merge or exit. However, size confers benefits regarding data collection and the adoption of telehealth systems, wearables and advanced equipment (AR HoloLens glasses, drones, AI), improving patient care and fostering quality competition. In the future, demographic trends and policy shifts will play a role in industry concentration and growth. The growing calls for nonemergency ambulance services from a growing older adult population will require increased funding, which insurance or private funds will need to provide. Private, large ambulance service providers may be able to compete on price for contracts, pushing less efficient public providers out of the market, a trend that may result in increased public-private partnerships. As healthcare reforms focus on efficiency, the shift to value-based care may shift from traditional fee-for-service payment models towards those rewarding cost-effectiveness and high-quality care that will spur the adoption of technology that provides the necessary data and metrics to assess performance. Amid all the demographic and structural changes, revenue is expected to strengthen at a CAGR of 2.3% through 2030, totaling $24.6 billion, with profit remaining stable at a 10.8% share of revenue.

By 2025, the alternative healthcare provider market in the United States is expected to be worth nearly ** billion U.S. dollars. This statistic shows a compilation of actual, estimated, and projected U.S. alternative healthcare providers and services annual revenues from 2013 to 2025. The term alternative medicine means any form of medicine that is outside the mainstream of western or conventional medicine as practiced by the majority of physicians, in hospitals, etc. Well-known examples of alternative medicine are: homeopathy, osteopathy, and acupuncture. Public opinion on alternative medicine Public opinion around using alternative medicine in the United States has generally been positive. A majority of men and women in the United States has reported that they were open-minded about using alternative medicine. By political affiliation, public opinion on using alternative medicine doesn’t shift dramatically either, as more than ** percent of both Republican and Democrat voters among adults, respectively, agreed that alternative medicine is a good supplement to cancer treatment. Alternative medicine in Europe Opinions about alternative medicine in Europe vary significantly from country to country. In France, a large majority of the population stated that they had an overall good image of alternative therapy. Similarly, in the United Kingdom, osteopathy was generally viewed as definitely or possibly an effective treatment for different illnesses. However, in Germany, a vast majority of adults stated that they still prefer traditional medicine over alternative medicine.

In relation to total revenue, the pharmaceutical industry is among the biggest investors in research and development (R&D). Based on data from the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry in the United States spent around ** percent of global revenues on R&D in 2023. Analyzing the revenues and R&D expenditure Members of the PhRMA trade group generated global revenues of approximately *** billion U.S. dollars in 2023, with domestic revenues accounting for over ** percent of that figure. With regard to R&D expenditure, PhRMA members spent some ** billion U.S. dollars worldwide in 2023, with spending in their domestic market accounting for around ** percent of the global figure. Product lifecycles in the pharmaceutical industry Pharmaceutical manufacturers require time and money if they are to develop new innovative medicines: it can take 10 to 15 years to develop a new medicine, at an average cost of approximately *** billion U.S. dollars. Due to patents and exclusivity, brand name drugs can expect to be on the market for an average of twelve years before a generic version enters. Generics contain the same active ingredients as branded drugs but can be considerably cheaper. The healthcare system in the United States generated around *** billion U.S. dollars in savings through generic medicines in 2022.